The growing awareness regarding the efficacies of human growth hormone therapies to treat a variety of disorders is creating high demand in the human growth hormone market. These medications are being used for the treatment of growth failure disorders (noonan syndrome, turner syndrome and idiopathic short stature), growth hormone deficiency, intestinal disorder (short bowel syndrome) and HIV-related weight loss or wasting. Public health regulatory agencies around the world have recognized the capabilities of growth hormone drugs and are granting approvals for use in various cases. For instance, in July 2018, the U.S. Food and Drug Administration (FDA) agency approved ZOMACTON, a growth hormone drug of Ferring Pharmaceuticals, for five additional pediatric indications such as idiopathic short stature, short stature associated with turner syndrome, growth failure in short stature homeobox-containing gene (SHOX) deficiency and short stature born small for gestational age (SGA). The agency also approved this drug for replacement of endogenous growth hormones in adults. Government agencies have also initiated campaigns to create awareness regarding early detection of growth disorders in children and to adopt growth hormone treatment. Thus, the growing awareness regarding multiple applications of growth hormone therapies is driving the demand in global human growth hormone market.
Request for Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_sample.php?id=701
Amidst the recent outbreak of COVID-19 pandemic, medical professionals and scientists are conducting research to develop growth hormone therapy for treatment of active COVID-19 patients and speed-up their recovery. These on-going research and development activities are anticipated to fuel the growth of global human growth hormone market.
In terms of revenue, global human growth hormone market was valued at US$ 4109.23 million in 2019 and is expected to reach US$ 5819.32 million by 2028, growing at an estimated growth rate of 8.9% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
The detailed research study provides qualitative and quantitative analysis of human growth hormone market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Enquiry Before Buying @ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=701
Key Findings of the Report:
- Based on route of administration, subcutaneous route contributes significant share of global human growth hormone market owing to the less incision and optimal drug delivery capabilities coupled with introduction of needle-free systems which further minimize the pain associated with growth hormone therapy.
- High number of children facing hormone deficiency compared to adults is driving the share of pediatric growth hormone deficiency (GHD) in global human growth hormone market.
- North America held the highest market share in global human growth hormone market in 2018. Asia Pacific is expected to register the highest compound annual growth rate (CAGR) over the period of next eight years. The flourishing biopharmaceutical industry and encouraging regulatory framework in the region is attracting global players to market their biosimilar human growth hormone products in the region.
- Some of the players operating in the human growth hormone market are AnkeBio Co., Ltd, Ascendis Pharma A/S, BTG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Ferring Pharmaceuticals, Ipsen Pharma, LifeTein, LLC., Merck Serono, Novo Nordisk Health Care AG, Pfizer Inc., Sandoz Inc. (Novartis AG), Teva Pharmaceutical Industries Ltd, Theratechnologies Inc., Versartis, Inc. and Vetter Pharma-Fertigung GmbH & Co. KG amongst others.
Request for Customization@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=701
Global Human Growth Hormone Market:
- By Route of Administration
- Subcutaneous
- Intramuscular
- Intravenous
- By Type
- Pediatric Growth Hormone Deficiency (GHD)
- Prader-Willi Syndrome
- Turner Syndrome
- Idiopathic Short Stature
- Small for Gestational Age
- Adult Growth Hormone Deficiency (GHD)
- Non-Weight Based
- Weight Based
- By Distribution Channel
- Hospitals
- Clinics
- Retail Pharmacies
- Others
- By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Get Full Information of this premium report@ https://www.absolutemarketsinsights.com/reports/Global-Human-Growth-Hormone-Market-2019-2027-701
About Us:
Absolute Markets Insights strives to be your main man in your business resolve by giving you insight into your products, market, marketing, competitors, and customers. Visit …
Contact Us:
Email id: [email protected]
Contact Name: Shreyas Tanna
Phone: +91-740-024-2424